Contributor Since 2008
NovaBay Pharmaceuticals Inc., a clinical-stage biotech company developing compounds to fight bacteria, fungi and viruses, presented a poster at the 2011 Conference of the Association for Research in Vision and Ophthalmology (ARVO) held this week in Fort Lauderdale, Fla.
The poster, titled “AganocideÂ® Compounds Effective Against Ophthalmic Pathogens,” highlights three new Aganocide compounds similar to NovaBay’s lead anti-infective Aganocide compound, NVC-422.
Novabay’s NVC-727, NVC-638, and NVC-704 compounds are broad-spectrum, fast-acting antimicrobial agents designed with the same mechanism of action but different activity profiles.
The three new compounds expand Novabay’s current portfolio of Aganocide compounds and open a door for the company to target other medical needs.
“NVC-727, NVC-638, and NVC-704 are very exciting new molecules in our growing portfolio of broad-spectrum, fast-acting, Aganocide compounds. These compounds also provide an opportunity to treat other unmet medical needs in dermatology, urology and wound care without development of resistance,” Mark Anderson, PhD, NovaBay’s chief scientific officer, stated in the press release. “In ophthalmology, we are uniquely positioned to develop an eye drop that will treat both bacterial and viral causes of conjunctivitis including Epidemic Keratoconjunctivitis also known as EKC.”
For more information visit novabaypharma.com
Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net